MaximusProfiticus
5 years ago
24th Oct 2019 16:05
(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with the Walter Reed Army Institute of Research (WRAIR) to conduct pre-clinical testing to evaluate novel combinations with 'iclaprim', to improve safety and efficacy administered by a novel enhanced aerosol technology, it announced on Thursday.
The AIM-traded firm said the aerosol technology allowed the delivery of antibiotics "painlessly and rapidly" into skin and soft tissue, with low-pressure and focused delivery.
It said the research was being funded through a grant from the US Department of Defense - Congressionally Directed Military Infectious Diseases Research Program, to evaluate the potential of using such a drug-device combination for wound care and to prevent and treat wound infections on the battlefield.
"When a wound becomes infected, it is critical to provide safe and effective treatment as fast as possible," said Motif Bio chief medical officer David Huang.
"The data generated from [research lead] Dr Zurawski's research will be important in understanding whether iclaprim delivered locally could play a role in treating battlefield wound infections."
Timing101
5 years ago
$MFTB
--
should remain on a watch list... and about the filing 6K , 10/25,
--
(ie) .. they have seventeen plus 6k's , so that was nothing new,
the real deal was the big blow back in FEB ...
--
They are restructuring ... is all in that phase.
--
One needs to look at how low will it go as it was once $10.00 and
moving nicely ... so TIME will tell.
--
Now if they were doing NOTHING .. then Nothing would happen,
--
they control alot internally .. and are pretty transparent about what they are doing.. they do not want to lose their trading status obviously.
$$$MADE
6 years ago
LOVE IT!! The Company also has plans to develop iclaprim for hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), as there is a high unmet need for new therapies in this indication. A Phase 2 trial in patients with HABP has been successfully completed and a Phase 3 trial is being planned. Additionally, iclaprim has been granted orphan drug designation by the FDA for the treatment of Staphylococcus aureus lung infections in patients with cystic fibrosis and is in preclinical development for this indication. Iclaprim has received Qualified Infectious Disease Product (QIDP) designation from the FDA together with Fast Track status for the ABSSSI indication. If approved for the ABSSSI indication as a New Chemical Entity, iclaprim will be eligible for 10 years of market exclusivity in the U.S. from the date of first approval, under the Generating Antibiotic Incentives Now Act (the GAIN Act). In Europe, 10 years of market exclusivity is anticipated. Motif is also building a patent estate to provide additional protection for iclaprim and has two U.S. method of use patents issued that will expire in 2037.